Search

Your search keyword '"Wilgucki, Molly"' showing total 12 results
Start Over Author "Wilgucki, Molly"
12 results on '"Wilgucki, Molly"'

1. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Author

Nassar, Amin H., Kim, So Yeon, Aredo, Jacqueline V., Feng, Jamie, Shepherd, Frances, Xu, Chao, Kaldas, David, Gray, Jhanelle E., Dilling, Thomas J., Neal, Joel W., Wakelee, Heather A., Liu, Yufei, Lin, Steven H., Abuali, Tariq, Amini, Arya, Nie, Yunan, Patil, Tejas, Lobachov, Anastasiya, Bar, Jair, Fitzgerald, Bailey, Fujiwara, Yu, Marron, Thomas U., Thummalapalli, Rohit, Yu, Helena, Owen, Dwight H., Sharp, John, Farid, Saira, Rocha, Pedro, Arriola, Edurne, D’Aiello, Angelica, Cheng, Haiying, Whitaker, Ryan, Parikh, Kaushal, Ashara, Yash, Chen, Luxi, Sankar, Kamya, Harris, Jeremy P., Nagasaka, Misako, Ayanambakkam, Adanma, Velazquez, Ana I., Ragavan, Meera, Lin, Jessica J., Piotrowska, Zofia, Wilgucki, Molly, Reuss, Joshua, Luders, Heike, Grohe, Christian, Baena Espinar, Javier, Feiner, Ella, Punekar, Salman R., Gupta, Shruti, Leal, Ticiana, Kwiatkowski, David J., Mak, Raymond H., Adib, Elio, Naqash, Abdul Rafeh, and Goldberg, Sarah B.

Published
2024
Full Text
View/download PDF

3. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC

Author

Nassar, Amin H., Jayakrishnan, Ritujith, Feng, Jamie, Shepherd, Frances, Adib, Elio, Cheung, Justin M., Lin, Jessica J., Liu, Yufei, Lin, Steven H., Parikh, Kaushal, Sridhar, Arthi, Shakya, Purnima, Dilling, Thomas J., Kaldas, David, Gray, Jhanelle E., Lobachov, Anastasiya, Bar, Jair, Luders, Heike, Grohe, Christian, Gupta, Shruti, Leal, Ticiana, Fitzgerald, Bailey, Crowley, Fionnuala, Fujiwara, Yu, Marron, Thomas U., Wilgucki, Molly, Reuss, Joshua, Chen, Luxi, Sankar, Kamya, Aredo, Jacqueline V., Neal, Joel W., Wakelee, Heather A., Thummalapalli, Rohit, Yu, Helena, Whitaker, Ryan, Velazquez, Ana, Ragavan, Meera, Cortellini, Alessio, Kwiatkowski, David J., Naqash, Abdul Rafeh, Goldberg, Sarah B., and Kim, So Yeon

Abstract

Patients with advanced ALK-positive NSCLC typically have poor response to immunotherapy; the benefit of consolidation durvalumab in patients with unresectable stage III ALK-positive NSCLC remains unclear. Herein, we compare the efficacy and safety of consolidation ALK tyrosine kinase inhibitor (TKI) versus durvalumab or observation after concurrent chemoradiation.

Published
2025
Full Text
View/download PDF

4. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Author

Nassar, Amin H., primary, Kim, So Yeon, additional, Aredo, Jacqueline V., additional, Feng, Jamie, additional, Shepherd, Frances, additional, Xu, Chao, additional, Kaldas, David, additional, Gray, Jhanelle E., additional, Dilling, Thomas J., additional, Neal, Joel W., additional, Wakelee, Heather A., additional, Liu, Yufei, additional, Lin, Steven H., additional, Abuali, Tariq, additional, Amini, Arya, additional, Nie, Yunan, additional, Patil, Tejas, additional, Lobachov, Anastasiya, additional, Bar, Jair, additional, Fitzgerald, Bailey, additional, Fujiwara, Yu, additional, Marron, Thomas U., additional, Thummalapalli, Rohit, additional, Yu, Helena, additional, Owen, Dwight H., additional, Sharp, John, additional, Farid, Saira, additional, Rocha, Pedro, additional, Arriola, Edurne, additional, D’Aiello, Angelica, additional, Cheng, Haiying, additional, Whitaker, Ryan, additional, Parikh, Kaushal, additional, Ashara, Yash, additional, Chen, Luxi, additional, Sankar, Kamya, additional, Harris, Jeremy P., additional, Nagasaka, Misako, additional, Ayanambakkam, Adanma, additional, Manana, Ana I., additional, Ragavan, Meera, additional, Lin, Jessica J., additional, Piotrowska, Zofia, additional, Wilgucki, Molly, additional, Reuss, Joshua, additional, Luders, Heike, additional, Grohe, Christian, additional, Espinar, Javier Baena, additional, Feiner, Ella, additional, Punekar, Salman R., additional, Gupta, Shruti, additional, Leal, Ticiana, additional, Kwiatkowski, David J., additional, Mak, Raymond H., additional, Adib, Elio, additional, Naqash, Abdul Rafeh, additional, and Goldberg, Sarah B., additional

Published
2024
Full Text
View/download PDF

7. 10-Year Breast Cancer Outcomes in Women ≤35 Years of Age

Author

Billena, Cole, primary, Wilgucki, Molly, additional, Flynn, Jessica, additional, Modlin, Leslie, additional, Tadros, Audree, additional, Razavi, Pedram, additional, Braunstein, Lior Z., additional, Gillespie, Erin, additional, Cahlon, Oren, additional, McCormick, Beryl, additional, Zhang, Zhigang, additional, Morrow, Monica, additional, Powell, Simon, additional, and Khan, Atif J., additional

Published
2021
Full Text
View/download PDF

8. Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective

Author

Braunstein, Lior Z., primary, Thor, Maria, additional, Flynn, Jessica, additional, Cost, Zachary, additional, Wilgucki, Molly, additional, Rosenbaum, Shalom, additional, Zhang, Zhigang, additional, Gillespie, Erin, additional, McCormick, Beryl, additional, Khan, Atif, additional, Ho, Alice, additional, Cahlon, Oren, additional, Deasy, Joseph O., additional, and Powell, Simon N., additional

Published
2019
Full Text
View/download PDF

9. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation

Author

Ho, Alice Y., primary, Olm-Shipman, Molly, additional, Zhang, Zhigang, additional, Siu, Chun Ting, additional, Wilgucki, Molly, additional, Phung, Anh, additional, Arnold, Brittany B., additional, Porinchak, Marypat, additional, Lacouture, Mario, additional, McCormick, Beryl, additional, Powell, Simon N., additional, and Gelblum, Daphna Y., additional

Published
2018
Full Text
View/download PDF

10. Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.

Author

Ho, Alice, primary, Barker, Christopher Andrew, additional, Gucalp, Ayca, additional, Lebron-Zapata, Lizza, additional, Wen, Yong Hannah, additional, Phung, Anh, additional, Wilgucki, Molly, additional, Henrich, Micaela, additional, Arnold, Brittany, additional, Patil, Sujata, additional, and McArthur, Heather L., additional

Published
2017
Full Text
View/download PDF

11. Morphologic Features of Magnetic Resonance Imaging as a Surrogate of Capsular Contracture in Breast Cancer Patients With Implant-based Reconstructions

Author

Tyagi, Neelam, primary, Sutton, Elizabeth, additional, Hunt, Margie, additional, Zhang, Jing, additional, Oh, Jung Hun, additional, Apte, Aditya, additional, Mechalakos, James, additional, Wilgucki, Molly, additional, Gelb, Emily, additional, Mehrara, Babak, additional, Matros, Evan, additional, and Ho, Alice, additional

Published
2017
Full Text
View/download PDF

12. Osimertinib and Capmatinib Combination Therapy to Overcome METY1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Author

Wilgucki, Molly, Yeung, Vincent, Ho, Grace, Bravo Montenegro, Gabriela L., Jones, Greg, Reuss, Joshua E., Liu, Stephen V., and Kim, Chul

Abstract

Osimertinib, a third-generation EGFRtyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by a heterogeneous array of resistance mechanisms. Activation of the METsignaling pathway by means of amplification has been implicated in resistance to osimertinib, but activation caused by point mutations in METhas not been well described.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results